Shilpa Gupta, Director of Genitourinary Oncology and a Professor of Medicine at Cleveland Clinic, reshared a post by Neeraj Agarwal, Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, on X, adding:
“Double congratulations Neeraj Agarwal, Arun Azad, Karim Fizazi and entire TALAPRO-2 team.
Great to see this QOL data from TALAPRO-2 & very reassuring to see QOL not compromised with this regimen for patients.”
Quoting Neeraj Agarwal‘s post:
“Just in Two The Lancet Oncology papers on patient-reported QOL results in ph3 TALAPRO-2 trial in all-comer & HRR deficient mCRPC Prostate Cancer patients. Improved OS without compromising QOL.”
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.
Authors: Nobuaki Matsubara, et al.
